# To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects

> **NCT04525079** · PHASE1 · COMPLETED · sponsor: **Celltrion** · enrollment: 32 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **DRUG:** CT-P59
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04525079
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-18
- **Primary completion:** 2020-08-07
- **Final completion:** 2020-11-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04525079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04525079, "To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04525079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*